RR001 not checked

EIR Biotherapies s.r.l.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“RR001, a cell-based gene therapy administered following administration of chemotherapy (Nab-PTX 125 mg/mq and GEM 1000 mg/mq)”In the company’s words, NCT06861452 on ClinicalTrials.gov
Tested for
Locally Advanced Pancreatic Adenocarcinoma
Main trialPhase 1/2
“RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer. Phase I /IIa clinical trial (open label and non-randomized) to test the effects (safety \& efficacy) of increasing doses of RR001”In the company’s words, NCT06861452 on ClinicalTrials.gov

Other drugs for Locally Advanced Pancreatic Adenocarcinoma

All 201 drugs for Locally Advanced Pancreatic Adenocarcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 29 Jul 2027 Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma
Phase 1/2Authorised not given SNIPER-LTFU: Long-term follow-up study of patients administered with RR001 in the interventional Parent SNIPER study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow RR001

Following is part of Solo: you see every change to RR001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in